Results of total cholesterol screening for early diagnosis of dyslipidemia in Saint Petersburg children

Background. Сardiovascular diseases (CVDs) remain the leading cause of disability and mortality worldwide. Dyslipidemia is a major risk factor for CVD, with familial hypercholesterolemia (FH) being the most common hereditary form. Despite its high prevalence, timely identification of FH remains remarkably low. Some pilot studies have shown that lysosomal acid lipase deficiency (LAL-D), a rare disorder requiring differential diagnosis from type IIa dyslipidemia, may be underrecognized. Objective. To present the results of lipid profile analysis in 1,000 primary school-aged children (9–11 years) who underwent universal screening in Saint Petersburg. Design and methods. A total of 1,000 children aged 9 to 11 years 11 months and 30 days were examined. The study design included assessment of anthropometric parameters and total cholesterol (TC) levels in capillary blood. In cases of hypercholesterolemia, family history, comprehensive biochemical blood analysis, and carotid artery duplex scan were performed, along with exclusion of secondary causes of dyslipidemia. When indicated, lysosomal acid lipase (LAL) activity and genetic testing were conducted. Results. The cohort comprised 44.5 % girls and 55.5 % boys. The mean capillary blood TC level was 4.04 ± 0.94 mmol/L (range: 2.43–10.9 mmol/L). Among the 1,000 children, 87 (8.7 %) had TC >5.2 mmol/L: 50 boys (57.5 %) and 37 girls (42.5 %), with a median TC of 5.61 ± 1.02 mmol/L (range: 5.2–10.9 mmol/L). According to Simon Broome criteria, 8 children (0.8 %) with TC 7.95 ± 1.35 mmol/L and LDL-C 6.11 ± 0.71 mmol/L were diagnosed with FH; pathogenic or likely pathogenic mutations in the LDLR gene were confirmed in 4 children. LAL-D was excluded in all 8 children (100 %). Conclusion. These findings underscore the necessity of universal screening and lipid profile assessment in the pediatric population.

1. Barbarash OL, Karpov YuA, Panov AV, et al. Stable coronary artery disease. Clinical guidelines 2024. Russian Journal of Cardiology. 2024;29(9):6110. In Russian [Барбараш О.Л., Карпов Ю.А., Панов А.В. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110]. https://doi.org/10.15829/1560-4071-2024-6110

2. Yezhov MV, Bazhan SS, Yershova AI, et al. Clinical guidelines for familial hypercholesterolemia. Ateroskleroz=Atherosclerosis. 2019;15(1):58–98. In Russian [Ежов М.В., Бажан С.С., Ершова А.И. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58–98].

3. DeSantes K, Dodge A, Eickhoff J, et al. Improving Universal Pediatric Lipid Screening. The Journal of Pediatrics. 2017.

4. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia. J. Am. Coll. Cardiol. 2020;75:2553–2566

5. Van den Bosch SE, Corpeleijn WE, Hutten BA, Wiegman A. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. Genes 2023;14:669. https://doi.org/10.3390/genes14030669

6. Vallejo-Vaz AJ, De Marco M, Stevens CAT, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries — The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234–255.

7. Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, et al. Global perspective of familial hypercholesterolaemia: A cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398:1713–1725.

8. Brown MS, Goldstein JL. Biomedicine. Lowering LDL — not only how low, but how long? Science. 2006;311:1721–3.

9. Korneva V, Kuznetsova T, Julius U. The role of cumulative LDL cholesterol in cardiovascular disease development in patients with familial hypercholesterolemia. J Pers Med. 2022;12:71.

10. Yezhov MV, Sergienko IV, Kolmakova TE, et al. Familial hypercholesterolemia. Moscow: Patiss LLC, 2021. P. 84. In Russian [Ежов М.В., Сергиенко И.В., Колмакова Т.Е. и др. Семейная гиперхолестеринемия. М.: ООО «Патисс», 2021. С. 84].

11. Sustar U, Kordonouri O, Mlinaric M, et al. Universal screening for familial hypercholesterolemia in 2 populations. Genet Med. 2022 Oct;24(10):2103–2111. DOI:10.1016/j.gim.2022.06.010. Epub 2022 Aug 1. PMID: 35913489.

12. Raslova K, Donicova V, Gonova K, et al. Detecting familial hypercholesterolemia: An observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia. J Clin Lipidol. 2024 JulAug;18(4):e537–e547. DOI:10.1016/j.jacl.2024.03.009.

13. Thompson-Paul AM, Kraus EM, Porter RM, et al. Pediatric Lipid Screening Prevalence Using Nationwide Electronic Medical Records. JAMA Netw Open. 2024 Jul 1;7(7):e2421724. DOI:0.1001/jamanetworkopen.2024.21724. PMID: 39042409; PMCID: PMC11267408.

14. Zuurbier LC, Defesche JC, Wiegman A. Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands. Genes. 2021;12:1168. https://doi.org/10.3390/genes12081168

15. European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. Lancet. 2024 Jan 6;403(10421):55–66. DOI:10.1016/S0140-6736(23)01842-1.

16. Sadykova DI, Kamalova AA, Rakhmaeva RF, et al. Regional experience of universal screening for total cholesterol in children. Farmateka=Pharmaceutical library. 2023;4(5):104–108. In Russian [Садыкова Д.И., Камалова А.А., Рахмаева Р.Ф. и др. Региональный опыт проведения универсального скрининга на общий холестерин у детей. Фарматека. 2023;4(5):104–108]. https://doi.org/10.18565/pharmateca.2023.4-5.104-108

17. Emelianchik EYu, Moiseeva AM, Emelianchik VS, et al. The effectiveness of targeted screening of familial hypercholesterolemia in children and adults under 44 years of age: a retrospective and prospective observational study// CardioSomatics. 2024;15(1):19–30. In Russian [Емельянчик Е.Ю., Моисеева А.М., Емельянчик В.С. и др. Эффективность таргетного скрининга семейной гиперхолестеринемии у детей и взрослых до 44 лет: ретроспективно-проспективное наблюдательное исследование// CardioСоматика. 2024;15(1):19–30]. DOI: https://doi.org/10.17816/CS623868.

18. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020 Jan 1;41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455

19. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168–3209. DOI:10.1016/j.jacc.2018.11.002.

20. Association of Medical Geneticists, Union of Pediatricians of Russia, Russian Gastroenterological Association, Russian Transplant Society. Clinical recommendations. Other lipid accumulation disorders. Lysosomal acid lipase deficiency, 2023. In Russian [Ассоциация медицинских генетиков, Союз педиатров России, Российская гастроэнтерологическая ассоциация, Российское трансплантологическое общество. Клинические рекомендации. Другие нарушения накопления липидов. Дефицит лизосомной кислой липазы, 2023].

21. Reiner Ž, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency — an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235:21–30.

22. Demaret T, Lacaille F, Wicker C, et al. Sebelipase alfa enzyme replacement therapy in Wolman disease: a nationwide cohort with up to ten years of follow-up. Orphanet J Rare Dis. 2021;16:507.

23. Vijay S, Brassier A, Ghosh A, et al. Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies. Orphanet J Rare Dis. 2021;16:13.

24. Sustar U, Groselj U, Trebusak Podkrajsek K, et al. Early Discovery of Children With Lysosomal Acid Lipase Deficiency With the Universal Familial Hypercholesterolemia Screening Program. Front. Genet. 2022;13:936121. DOI:10.3389/fgene.2022.936121.

25. Ademi Z, Norman R, Pang J, at al. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment? Atherosclerosis. 2020 Jul:304:1–8. DOI:10.1016/j.atherosclerosis.2020.05.007.

26. Lázaro P, Pérez de Isla L, Watts GF, et al. Cost effectiveness of a Cascade Screening Program for the Early Detection of Familial Hypercholesterolemia. Journal of Clinical Lipidology. 2017. DOI:10.1016/j.jacl.2017.01.002.

27. Pelczarska A, Jakubczyk M, Jakubiak-Lasocka J. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland. Atherosclerosis. 2018 Mar;270:132–138. DOI:10.1016/j.atherosclerosis.2018.01.036.